# OnCo record future-super (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/future-super/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "future-super", "NCT04395989" ;
  schema:name "FUTURE-SUPER"@en ;
  schema:alternateName "FUTURE SUPER"@en, "NCT04395989"@en ;
  schema:description "FUTURE-SUPER tested a defined subtype-linked treatment strategy in advanced TNBC. The pooled phase 2 PFS comparison was positive; the current registry does not establish availability."@en ;
  schema:url <https://onco.cc/trials/future-super/> ;
  schema:dateModified "2026-11-09"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04395989>, <https://pubmed.ncbi.nlm.nih.gov/38211606/> ;
  onco:status "positive" ;
  onco:tag "education-audit", "subtyping-strategy" ;
  onco:phase "2" ;
  schema:startDate "2020-07-28" ;
  onco:related <https://onco.cc/key-papers/paper-future-super-lancet-oncology-2024/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/> ;
  onco:drugs <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/pyrotinib/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:terms <https://onco.cc/terms/tnbc-molecular-subtyping/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-future-super-lancet-oncology-2024/> .
